Background. Newborns with inborn errors of metabolism often present with hyperammonaemic coma, requiring prompt diagnosis and specific medical therapy, nutritional support and efficient toxin removal. Little information regarding the efficacy and safety of continuous venovenous haemodialysis (CVVHD) as an option for extracorporal ammonia detoxification in children is available. Results. Plasma ammonia levels (range 464-7267 μg/dl before dialysis and 27-3317μg/dl after dialysis) were significantly reduced by 50% within 4.7±2.5 h with CVVHD compared with 13.5±6.2 h with CPD (P<0.0001). Plasma ammonia levels <200 μg/dl critical range were achieved within 22.4±18.1 h in CVVHD patients compared with 35.0 ± 24.1 h with CPD. Depending on the weight and blood pressure stability of the patients, mean blood flow velocities of 9.8±3.4 ml/kg/min and mean dialysate flow rates of 3925 ± 2398 ml/min/1.73 m 2 were employed. Blood and dialysate flows significantly correlated with ammonia clearance and decay of ammonia in vivo. Because of the severe underlying disease, 18% of CVVHD patients died compared with 50% undergoing CPD. In total, 82% of CVVHD patients survived the first 6 months after dialysis. Among these, 43% were without sequelae, 43% developed moderate mental retardation, and two (14%) developed severe mental retardation. Conclusion. CVVHD effectively and quickly eliminates plasma ammonia. To optimize long-term mental outcome, rapid identification and appropriate treatment of the underlying disease as well as starting dialysis early are of enormous therapeutic value.
years of age, respectively] were admitted to our hospital for dialysis between 1996 and 2008. Seventeen children (15 neonates), received CVVHD. Four neonates received continuous peritoneal dialysis (CPD). All started medical treatment with sodium benzoate, L-arginine hydrochloride and carnitine as well as protein-restricted parenteral diets with high caloric intake before dialysis.
Results. Plasma ammonia levels (range 464-7267 μg/dl before dialysis and 27-3317μg/dl after dialysis) were significantly reduced by 50% within 4.7±2.5 h with CVVHD compared with 13.5±6.2 h with CPD (P<0.0001). Plasma ammonia levels <200 μg/dl critical range were achieved within 22.4±18.1 h in CVVHD patients compared with 35.0 ± 24.1 h with CPD. Depending on the weight and blood pressure stability of the patients, mean blood flow velocities of 9.8±3.4 ml/kg/min and mean dialysate flow rates of 3925 ± 2398 ml/min/1.73 m 2 were employed. Blood and dialysate flows significantly correlated with ammonia clearance and decay of ammonia in vivo. Because of the severe underlying disease, 18% of CVVHD patients died compared with 50% undergoing CPD. In total, 82% of CVVHD patients survived the first 6 months after dialysis. Among these, 43% were without sequelae,
Introduction
Hyperammonaemia due to inborn errors of metabolism is a rare condition which requires immediate recognition and intervention to prevent long-term mental retardation and fatal outcome [1] . Inborn errors of metabolism comprise urea-cycle defects and organic acidaemias. While argininosuccinate synthetase deficiency (AS def), ornithin transcarbamylase deficiency (OTCD), carbamylphosphate synthetase deficiency (CPSD) and argininaemia are ureacycle defects, propionic acidaemia (PA), glutaric aciduria type II and methylmalonic acidaemia (MMA) are organic acidaemias. Children with urea-cycle defects and organic acidaemias often present with metabolic acidosis, hyperammonaemia and clinical symptoms of acute metabolic encephalopathy including seizures, apnoea or coma within the first days of life [1, 2] . The duration and extent of hyperammonaemia predict the neurological outcome [1, 3, 5, 6] , making immediate removal of ammonia a critical issue. Conservative treatment encompasses several methods to reduce ammonia production including high caloric intake, inducing anabolism to achieve reduced proteolysis, and a protein-restricted diet, which are the basis of therapy and necessary to prevent ammonia accumulation. Furthermore, depending on the underlying disease, substitution of L-arginine hydrochloride, sodium benzoate and/or sodium phenylbutyrate employs alternative pathways for the excretion of nitrogen-containing degradation products [3, 4] . This treatment is often initiated too late for various reasons, e.g. delayed identification of hyperammonaemia as an underlying cause of clinical symptoms [3] or when the ammonia generation is too high to be quickly reversed by conservative therapy. In these cases, plasma ammonia has already accumulated, and additional dialysis is the only option remaining for rapid detoxification [5, 6] . Two different dialysis techniques are considered to be favourable in these patients; continuous peritoneal dialysis (CPD) and haemodialysis (HD). CPD is safe but requires a surgically or interventionally implanted catheter and includes a risk of peritonitis and sepsis with a high mortality, especially in newborns [7] . Before the mid-1990s, CPD was used for ammonia detoxification because extracorporal dialysis was technically very difficult and risky in neonates [8, 9] . Within the past 10 to 15 years, technical developments made HD, especially continuous techniques [continuous venovenous haemodialysis (CVVHD), continuous venovenous haemodiafiltration (CVVHDF) or continuous venovenous haemofiltration (CVVHF)], suitable for neonates by reducing the volume of the extracorporal circuit, having pumps that work with high accuracy, and by providing small-sized central venous catheters [10] [11] [12] [13] . Publications comparing both techniques tend towards a superior ammonia clearance for HD versus CPD, but these are limited to small numbers of patients because neonatal hyperammonaemia is a rare condition [5, [14] [15] [16] . Therefore, studies beyond these case reports are needed to obtain more information regarding acute management. We retrospectively analysed data from 21 patients with hyperammonaemia, most of whom were neonates, who received either CVVHD or CPD treatment as rescue therapy. To our knowledge, this is the largest neonatal series reported so far. Our analysis was aimed toward answering the following questions: (i) is CVVHD a safe and reliable method for use in neonates? (ii) how much does the reduction of plasma ammonia depend on technical parameters such as blood and dialysate flow velocities? and (iii) how long does it take to achieve ammonia levels below the toxic level in children undergoing CVVHD or CPD?
Materials and methods

Patients
From 1996 to 2008, 21 patients (17 males and four females, Tables 1 and  2 ) were referred to our hospital for ammonia detoxification. All 21 are included in this retrospective analysis. Nineteen patients were neonates with a mean age of 4.1±2.4 days (range, 2-10 days) and a mean birth weight of 3381±1016 g (Tables 1 and 2 ). Two patients were older at 1 and 7 years of age (Table 1) . Citrullinaemia due to AS def was diagnosed in eight patients, OTCD in three patients, MMA in two patients, CPSD in three patients, PA in one patient, glutaric aciduria type II in one patient and argininaemia in one patient. The diagnosis of two patients remained unclear, even after an extensive post-mortem analysis including muscle and liver biopsies as well as fibroblast cultures and genetic testing, which did not suggest a plausible diagnosis. The peak plasma ammonia level in one of these patients was very high at 7267 μg/dl. The patients initially presented with somnolence, seizures, tachypnoeia, flop- AS def, argininosuccinate synthetase deficiency; OTCD, ornithin transcarbamylase deficiency; MMA, methylmalonic acidaemia; CPSD, carbamylphosphate synthetase deficiency; PA, propionic acidaemia; Glut. Acid. II, glutaric aciduria type II.
piness, poor feeding, apathy, respiratory insufficiency or coma (Tables 1  and 2 ). Diagnoses for other patients were confirmed by the Department of Metabolic Diseases at the Children's Hospital of the University of Düsseldorf, Germany or the Department of Metabolic Diseases at the Children's Hospital of the University of Heidelberg, Germany.
Conservative treatment
At primary diagnosis of hyperammonaemia, all patients initially received conservative supportive treatment consisting of protein-free parenteral nutrition and high caloric intake (25 g/kg/day glucose, which was equivalent to 100 kcal/kg/day). Fifteen of 21 patients received insulin to target blood glucose levels of 100-200 mg/dl (0.05-0.1 IU/kg/h). Patients with urea-cycle disorders received intravenous sodium benzoate at a loading dose of 250 mg/kg over 90 min, followed by a maintenance infusion of 250-300 mg/kg/day until the ammonia levels were lowered. In addition, L-arginine hydrochloride was administered at a starting dose of 2 mmol/kg within 90 min followed by a continuous infusion of 2 mmol/kg/day. L-Carnitine was given at a dose of 100 mg/kg/day. Eleven patients received sodium phenylbutyrate (250-500 mg/kg/day). Two patients received an exchange transfusion: one patient with citrullinaemia in 1996 and one patient with MMA in 2006 because dialysis had to be stopped temporarily due to bleeding from the catheter exit site. General supportive care aimed at correcting electrolyte and fluid imbalances, and ventilatory (n=19) and circulatory support with catecholamines (n=3) was also given. ; Fresenius Medical Care, Bad Homburg, Germany). In one patient in 1996 (No. 1), CVVHD was performed using a NFG05 device (Dialysetechnik, Munich, Germany). A bicarbonate-buffered electrolyte solution was used as the dialysis fluid (e.g. Duosol, Braun, Melsungen, Germany). The extracorporal circuit volume was 32ml (Baxter, Ettlingen, Germany). The system was prefilled with blood in 59% of cases to minimize arterial hypotension according to the discretion of the paediatric nephrologists. Seventeen patients received CVVHD (Table 3) . Shaldon catheters (6.5 F, polyurethane GamCath Catheters, Gambro, Hechingen, Germany) were used as vascular access in all patients receiving continuous haemodialysis. The Shaldon catheter was inserted in either the right (n=8) or the left femoral vein (n=5), the right jugular vein (n=2) or the left subclavian vein (n=2; Table 3 ). In one patient, the Shaldon catheter site was changed due to bleeding from the right femoral vein. Blood flow and dialysate flow velocities were chosen by the paediatric nephrologists responsible, depending on the blood pressure and weight of the patient (blood flow: 5-15 ml/kg/min, dialysate flow of approximately 2000 ml/m 2 body surface/h). Blood flow velocities between 22 and 50 ml/min were achieved in neonates and between 80 and 120 ml/min in older children. Heparin was used for anticoagulation with a loading dose of 50-100 IE/kg body weight and a maintenance dose of 10-30 IE/kg/h body weight, which was adjusted during dialysis to achieve an activated clotting time (ACT) between 120 and 140 s.
Before 1998, CPD was performed in patients with hyperammonaemia (n=4; Table 4), and coiled single-cuff Tenckhoff catheters (flex-Neck, MedigroupInc, Oswego, IL, USA) were surgically inserted into the peritoneum. Fill volumes ranged from 10 to 25 ml/kg body weight with a dwell time of 60 min. Dialysis solutions were standard bicarbonate-buffered with 2.3% glucose concentration (Table 4) .
Assessment of clinical outcome
Since long-term supervision of these patients was not performed in our hospital and patients were referred shortly after detoxification to a centre for metabolic disorders near their home, we did not have access to a standardized assessment of their mental development. Therefore, our information regarding their long-term outcome is based on the information and cooperation from their families and doctors. Patients were classified into three groups: patients with normal mental development, patients who showed moderate alterations and delay in their mental development but could be integrated in specialized school and nursery schools and those with severe mental retardation. The follow-up time after dialysis ranged from 6 months to 11 years.
Laboratory methods Measurement of plasma ammonia levels. Ammonia was determined in EDTA plasma every 2-4 h using glutamate dehydrogenase (automatic clinical analyser; Dade Behring, Deerfield, IL, USA; normal range 20-90 μg/dl).
Clearance calculations. Direct ammonia and urea clearances using the pre-and post-dialyser metabolite concentrations were calculated in four CVVHD and two CPD patients but not in the majority of patients on a regular basis. To generate more data and to evaluate the efficacy of ammonia and urea removal, clearances within 30 to 60 min after starting dialysis treatment were calculated, based on the measured blood ammonia and urea decay, according to the formula: Clearanceðml=minÞ = blood flowðml=minÞ Â ðCpre−CpostÞ=Cpre:
Cpre and Cpost are the metabolite blood concentrations measured before starting dialysis and after 30 to 60 min, respectively.
Dialysate clearances in CPD patients were calculated according to the formula: 
Statistical analysis
Statistical analysis was performed using GraphPad Prism© (version 5.01 for Windows, GraphPad Software, San Diego, CA, USA). Auxologic parameter data are described as means±SD. The level of statistical significance was predefined as α=0.05, and the resulting P values are given descriptively. Ammonia blood concentration values obtained between the start and the end of dialysis were used to fit monoexponential decay curves, and the time required to reduce the initial metabolite concentration by 50% was calculated accordingly. Correlations were performed by linear regression analysis using Pearson's correlation coefficient. The significance of statistical analyses comparing the effectiveness of CVVHD and CPD is limited because of the small numbers of patients.
Results
Technical modalities
Shaldon catheters were inserted in 15 neonates and the two older children without major complications (Table 3) . In one patient, the catheter site had to be changed due to sudden bleeding at the catheter exit site; 2 days after removal of the catheter, thrombosis of the femoral vein was diagnosed. In total, three patients developed venous thrombosis of the femoral or iliacal vein after insertion of the Shaldon catheter, which resolved after administration of intravenous heparin. One patient with a femoral Shaldon catheter temporarily experienced swelling of the adjacent leg because the diameter of the inserted catheter led to a nearly complete blockage of the vein without evidence of a venous thrombosis. Blood flow and dialysate flow rates were adjusted by the paediatric nephrologist responsible, depending on the blood pressure and weight of the patients.
The mean blood flow velocities of 9.8 ± 3.4 ml/kg/min (range, 3.7-22.7 ml/kg/min) and mean solute flows of 3925±2398 ml/min/1.73 m 2 (range, 838-11545 ml/min/ 1.73 m 2 ) were employed. Short episodes of arterial hypotension occurred in seven of 17 CVVHD patients after the start of CVVHD. These were resolved with a sodium chloride (0.9%) infusion. Catecholamines were used in three of 17 patients in alternating doses around the start of dialysis but remained stable during the rest of the CVVHD treatment. All these patients received catecholamines before starting dialysis. In CPD patients, no technical difficulties were encountered.
Plasma ammonia
Plasma ammonia levels ranged from 464 to 7267 μg/dl before dialysis and from 27 to 3317 μg/dl after dialysis. The mean plasma ammonia level before dialysis was 1717±1643 μg/dl in CVVHD patients and 900±517 μg/ dl in CPD patients. Plasma ammonia levels were significantly reduced by 50% within 4.7±2.5 h with CVVHD (Table 3 ) compared with 13.5±6.2 h with CPD (Table  4 ; P<0.0001). In patients treated with CVVHD, plasma ammonia levels below the critical level of 200 μg/dl [16, 17] were achieved within 22.4±18.1 h compared with 35.0±24.1 h in patients treated with CPD (P=0.37; Tables 3 and 4). In 65% (11 of 17 patients), a lasting detoxification beyond 200μg/dl was achieved in less than 20 h. Total dialysis time was 42.0±30.4 h for patients treated with CVVHD and 59.4±87.2 h for patients treated with CPD (P=0.33). We observed a significant correlation between the percentage decay of ammonia within 6h after starting dialysis and the ratio of time-averaged dialysate flows/blood flows (Figure 1 ). An increase of this ratio led to a higher percentage of ammonia decay (Pearson r=-0.65; P=0.0068; Figure 1 ). Clearance calculations of the metabolites ammonia and urea were directly calculated as pre-and post-dialysis concentrations in four CVVHD and two CPD patients. To generate additional clearance estimates, we performed similar but indirect calculations using the ammonia and urea decay within 30-60min in the remaining patients. Ammonia and urea clearances also showed significant differences between patients treated with CVVHD and CPD (e.g. ammonia was 18.9 ± 7.7 ml/min with CVVHD vs. 1.4 ± 1.1 ml/ min with CPD, Tables 3 and 4, Figure 2 ). As demonstrated for the blood ammonia decay, ammonia and urea clearances were significantly dependent on blood flow, urea clearance and dialysate flow rates (Figure 2 ). Directly and indirectly measured pre-and post-dialysis clearances were in the same range, although one would expect a K-overestimation in patients in whom we used an indirect estimation. Peak ammonia levels did not correlate with mental outcome. Stratifying our patients into groups depending on peak ammonia levels below or greater than 1500μg/dl were not different concerning mental outcome (data not shown).
Assessment of mental status
Coma duration was difficult to assess because 19 patients needed ventilatory support before or shortly after referral to our clinic; three of the 21 patients received sedatives, and 16 received phenobarbitol as an anticonvulsant. Therefore, the degree of vigilance of these patients was impaired. A standardized coma score for newborn patients was not established in our hospital and varies among hospitals. Accordingly, a clear classification of coma level prior to ventilation was not possible and depended on the personal rating of the paediatrician on call. In this light, a correlation between coma duration and mental outcome is not easily assessed. The time between the start of supportive medical treatment and initiation of dialysis was not different between CVVHD and CPD patients (CVVHD, 8.9±6.3 h vs. CPD, 8.8±5.3 h).
Outcome
The length of stay in our hospital depended on the time in which the patients reached stable condition without dialysis and tended to be longer for those treated with CPD. However, this difference did not reach significance (CVVHD, 6.5 ± 4.6 days vs. CPD 8.3 ± 4.4 days; P = 0.579). Two of 15 neonates (13%) undergoing CVVHD died on Days 2-3; one newborn had glutaric aciduria type II, and the diagnosis of the other newborn remained unclear. The peak ammonia levels in these patients were 907 μg/dl and 7267 μg/dl, respectively. Half of the neonatal CPD patients (two of four) died on Day 3; one was diagnosed with CPSD, while the diagnosis of the other patient remained unclear. One infant undergoing CVVHD died of multi-organ failure after 13 days because of sepsis caused by Pseudomonas aeruginosa.
In total, 82% (n = 14) of the 17 patients in the CVVHD group survived the first 6 months after dialysis. Among those, 43% (n= 6) were without sequelae and 43% developed moderate mental retardation. Two patients (14%) developed severe mental retardation. The survival rate in the CPD group was 50%. The two surviving patients in the CPD group developed moderate mental retardation.
Outcomes stratified for underlying disease Patients with citrullinaemia. Four of seven patients (57%) with citrullinaemia who received CVVHD had a normal mental development (observation period, 6-20 months). Three patients had moderate retardation (observation period, 10 months to 11 years). One patient with citrullinaemia was treated with peritoneal dialysis and had moderate mental retardation. None of the patients with citrullinaemia died.
Other underlying diseases. In contrast, only two of 10 patients (20%) with other underlying diseases treated with CVVHD had a normal mental outcome. One had OTCD and one MMA. Five of 10 patients (50%) had moderate to severe mental retardation (two with CPSD, one with OTCD, one with argininaemia and one with PA). Three of 17 children undergoing CVVHD died. One patient had glutaric aciduria type II, one had MMA, and one patient's diagnosis remained unclear. Of the four patients receiving peritoneal dialysis, two died; one with CPSD and one for whom the diagnosis remained unclear. Two patients receiving peritoneal dialysis had moderate mental retardation (CPSD).
Discussion
In our retrospective analysis of patients with hyperammonaemia provided adequate conservative treatment, we show that CVVHD is safe and led to a faster reduction of plasma ammonia than CPD in a considerably high number of predominately neonatal patients. CVVHD, HD and CPD are reported to be effective treatment options in hyperammonaemic metabolic crises, with acute HD providing far greater metabolite clearance than CVVHD or CPD [14, 16] . However, due to the practicability in neonates, acute HD has never been an option for our patients; therefore, it could not be compared directly with either of these modalities. Our results from a larger patient cohort support the observations of smaller, previously published reports showing superior eff icacy of HD techniques compared with CPD [5, 14, 15] . The long-term outcome in the CVVHD group showed a mortality rate of 13% among the neonatal patients, which was better than the 50% mortality in the CPD group. Survival without mental retardation was observed in 43% of the surviving CVVHD patients, while none of the CPD patients survived with normal mental development.
Schaefer and co-workers demonstrated a strong correlation between ammonia clearance and blood flow velocities in the experimental setting of a simulation study [5] . In accordance with this study, we show a significant correlation in vivo between the time-averaged mean ratio of solute flows/dialysate flows and the percentage ammonia decay from initial values within 6 h. The calculated ammonia and urea clearance also show a significant dependency on blood and dialysate flow rates with regard to ammonia. Respectively, a weakness of this study was that we did not perform pre-and post-dialysis clearances in all patients on a regular basis. However, directly calculated and indirectly estimated clearances were in the same range. Among those parameters, the blood ammonia decay is the most important biological efficiency marker, although these were largely affected by anaand catabolism. We chose the relatively short time line of 6 h to minimize the influence of the ammonia generation rate. We cannot completely exclude the possibility that some patients were in different metabolic conditions, but all children received standard parenteral nutrition with a minimum of 100 kcal/kg/d, mostly based on high glucose with protein restriction. Insulin was administered to achieve anabolism and to avoid blood glucose levels greater than 120 mg/dl. Therefore, the ammonia decay time seems to be a reliable marker of dialysis efficiency in a standardized setting with the same caloric support.
When evaluating therapeutic efficacy, it should be taken into account that not only ammonia showed good clearance characteristics but also co-medications such as sodium phenylacetate or sodium benzoate, as demonstrated for HD and HF [18] . This may lead to a reduced efficacy of the conservative treatment. On the contrary, a larger clearance of amino acids such as citrulline, glycine or glutamine may enhance the efficacy by providing additional nitrogen removal [19] .
Our retrospective analysis has several limitations, among which is the absence of an initial coma score, and only vague speculations on the overall coma duration. Previous studies have reported that the overall duration of coma, and not the peak ammonia level and the total time of hyperammonaemic crisis, is the predominant predictor of the neurological outcome [5, 6] . However, there is also no doubt that blood ammonia must be reduced to a non-toxic range as quickly as possible to improve the outcome [16, 17] . The mortality rate in the neonatal and overall CVVHD group was low compared with the reported mortality rates of between 33% and 40% in this group of patients [5, 6] . We found similarly high mortality rates in the CPD group, where survival was 50%. In this respect, our study clearly shows that our procedures with comparably short intervals between start of supporting medication and dialysis have been successful, with a short 50% ammonia reduction time, comparably short dialysis time and only a few side effects [5, 6] .
After stratifying our patients according to their underlying disease, the best outcome was observed in the group of patients with neonatal onset citrullinaemia. Thirty-eight percent of our patients (n=8) were diagnosed with citrullinaemia. The incidence of this disease is reported to be between 1:57 000 (USA) and 1:1 616 000 (Finland) [20, 21] . Our considerably higher number of patients may be due to the large area covered by our dialysis unit, which includes a mixed ethnic population that is 73% Turkish in origin. Only 14% of our patients were Caucasians, 9% were Asians, and one patient was from Greece. In this context, it is interesting to mention a single-centre Turkish study where 23 patients were diagnosed with citrullinaemia within 20 years [22] , assuming a higher incidence of citrullinaemia in this area. None of our patients with citrullinaemia died. In four of seven children (57%), normal mental development was achieved; all of these patients received CVVHD. One patient undergoing CPD treatment developed moderate mental retardation. Citrullinaemia is not described as having a favourable outcome per se, and patients with the neonatal form have been shown to have mortality rates of 40-100% [20, 22, 23] . In this context, our results are considerably positive.
The duration of the overall treatment is also a remarkable point. Since the duration on dialysis was considerably shorter for patients undergoing CVVHD treatment compared with CPD, CVVHD patients could be discharged earlier. As dwell times in CPD have to be as short as 30-60 min to achieve a considerable reduction in plasma ammonia, one-to-one nursing is necessary, requiring more personnel resources.
Besides conservative therapy, detoxification through temporary dialysis in cases of acute decompensation significantly improves the outcome of patients with hyperammonaemia due to inborn errors of metabolism. Nevertheless, early detection of the underlying metabolic disease and rapid initiation of sufficient drug therapy continues to be essential to achieve a good neurological outcome. In cases of organic aciduria, e. g. in patients with MMA where hyperammonaemic conditions may dramatically decrease within hours, early detection of the underlying disorder is the predominant challenge since it can prevent the patient from receiving dialysis [24] . Blood purification must be considered as rescue therapy in cases where conservative treatment fails to prevent or attenuate ammonia accumulation. In these cases, dialysis can improve patients' outcome.
However, both treatment options cannot avoid the occasional acute metabolic decompensation that can occur in children for whom no curative therapies exist as yet. This makes the long-term outcome unpredictable for families of the affected children. Therefore, future therapeutic strategies focus on alternative, preferably curative options such as gene therapy, orthotopic liver transplantation or liver cell transplantation, which has been carried out in pilot trials [25] [26] [27] .
Conclusions
CVVHD in newborns seems to be an effective modality to quickly eliminate plasma ammonia. It should be performed exclusively by highly experienced personnel at paediatric nephrology centres or neonatal ICUs. Our series suggests that CVVHD has benefits over CPD in the treatment of hyperammonaemia. We are aware that intermittent HD can lead to even more pronounced advantages in overall survival, but in the light of other dis-advantages, CVVHD seems to be the method of choice in neonates under unstable haemodynamic conditions. The immediate and long-term survival is highly dependent on aggressive management to improve the neurological outcome, and other as yet unknown strategies might be required to guarantee the best possible treatment. Initially, rapid identification of the underlying disease followed by immediate initiation of treatment and starting dialysis early are of enormous therapeutic value.
